INTIMATION FOR BODHIKA SEMINAR - 21/2/2022
NAME OF GUIDE: DR ASWATHY S MD (Ay)
DATE: 21/02/2022
TIME: 2:00-4:00 PM
VENUE: MICROSOFT TEAMS
ABSTRACT
Microalbuminuria (MAU) is defined as
levels of albumin ranging from 30-299 mg in a 24-h urine collection and is an
important predictor of Diabetic Nephropathy. Diabetes Mellitus has become an
ever-growing world-wide health problem in all socio-economic groups. India
currently represents 49 percent of the world’s diabetes burden, with an
estimated 72 million cases in 2017, a figure expected to almost double to 134
million by 2025. The increasing incidence of the disease elevates its
complications ranging from acute, life-threatening conditions such as severe hypoglycemia
or ketoacidosis to chronic, debilitating complications affecting multiple organ
systems such as retinopathy, nephropathy, neuropathy and cardiovascular
disease. Out of these, Diabetic Nephropathy (DN) occuring due to
microangiopathies is definitely on a rise. The earliest clinical evidence of
Diabetic Nephropathy is Microalbuminuria (MAU) as defined as 30-299 mg/d in a
24 –hour collection. Since MAU is the prime marker for early suspection to
renal affliction, the need of studies with regard to reducing MAU and
maintaining glycemic control becomes important.
The drug of study is Gokshuradi Guggulu
mentioned in Yogaratnakara – Mehaadhikara, indicated in
conditions of prameha, vataroga, vatasonita, mutraghata, mutradosha and pradara.
In addition, the ingredients are
primarily found to be pramehahara and rasayana with special
affinity to vasti and mutravahasrotas. The study is intended to
evaluate the effect of the drug in reducing microalbuminuria associated with
Type 2 DM. The trial drug is administered in a dose of 2 gutikas of 500
mg each thrice a day, half an hour before food with lukewarm water for a period
of 30 days. A sample size of 23 patients aged between 35 to 65 years with known
Type 2 Diabetes Mellitus and urine albumin within the range of 30-299 mg in
24-hr urine sample are selected according to inclusion and exclusion criteria.
Level of urine microalbumin in 24-hr urine sample is noted before the study and
after one month on the 31st day. The data collected will be statistically
analysed.
IN GENERALISED ANXIETY DSORDER
NAME OF GUIDE: DR BINDU P R MD (Ay)
NAME OF CO-GUIDE: DR KIRAN KUMAR S
DATE: 21/02/2022
TIME: 2:00-4:00 PM
VENUE: MICROSOFT TEAMS
ABSTRACT
Generalised anxiety disorder is characterized by persistent and excessive worry plus some combination of motor tensions (restlessness, fatigue) autonomic hyperactivity (palpitations, dry mouth) exaggerated startle response, trouble falling asleep. Prevalence of anxiety in general population is 10.15%. It is twice as more common in females than in males and in elderly age group. According to epidemiological survey one third of the population is affected by an anxiety disorder in their lifetime. This excessive worry often interferes with daily functioning, and sufferers are overly concerned about every day matters. Majority of the psychiatric illness are grouped under unmada and apasmara chapters mentioned in the classics of Ayurveda. Anxiety can be considered as a preclinical condition and can be compared to unmada purvarupa. Abheerumooladi kashaya yoga mentioned in Arogya Kalpadruma contains 3 drugs of which sankupushpi have scientifically proved anxiolytic activity, and satavari having antidepressant activity. The primary aim of the study is to evaluate the effect of Abheerumooladi kashaya yoga in reducing the signs and symptoms of Generalised anxiety disorder. It is an interventional study-pre and post without control group. The study sample will be 30. Male and female patients of the age group 20-50 years attending the OPD of Department of Kayachikitsa, Government Ayurveda College, Thiruvananthapuram, who were diagnosed cases of Generalised Anxiety Disorder based on ICD10 Criteria will be included in the study. Patients with organic psychiatric disorder, severe systemic diseases like cardiac problems, malignancy, tuberculosis, hyperthyroidism, drug abuse, and withdrawal patients will be excluded. The informed consent will be obtained from the patient. They will be subjected to detailed clinical evaluation and the data will be recorded. The study will be conducted in single group. The triall drug Ahbeerumooladi kashaya yoga will be given to subject as kashaya extract for 45 days. They will be advised to take the extract form of medicine with 60ml lukewarm water along with ghrita 10 ml as anupana twice daily, in empty stomach for a period of 45 days. Thirty sachets will be given to them at an interval of fifteen days. A total of 90 sachets will be given to the patients during the study period. Patients will be encouraged for regular visits at the OPD at an interval of fifteen days for uninterrupted feedback. During the visit they will advised to bring back the labeled sachet in order to make sure their drug intake. The signs and symptoms of the patient will be assessed on 0th,15th,30th ,45th day. The result obtained will be statically analysed.
No comments:
Post a Comment